TABLE 1

Demographics and Characteristics of Patients

Patient blood identifier	Sex	Age at treatment (y)	Body weight (kg)	Diagnosis	Primary site	Treatments before PRRT	5-FU in combination with PRRT
P1.1	M	46	98	Neuroendocrine	Pancreas	Chemotherapy	+
P1.2	M	47	96	Neuroendocrine	Pancreas	Chemotherapy	+
P1.3	M	47	100.4	Neuroendocrine	Pancreas	Chemotherapy	+
P2.2	M	62	82.3	Carcinoid	Small bowel	Nil	−
P2.3	M	62	82	Carcinoid	Small bowel	Nil	+
P2.5	M	62	80.1	Carcinoid	Small bowel	Nil	+
P3.3	F	46	133	Neuroendocrine	Small bowel	Nil	+
P3.4	F	46	130	Neuroendocrine	Small bowel	Nil	+
P4.1	M	55	77	Carcinoid	Bowel	Surgery	−
P5.1	F	52	79	Neuroendocrine	Small bowel	Chemotherapy/Sandostatin	+
P6.1	M	57	81	Neuroendocrine	Pancreas	Sandostatin	−
P7.3	F	49	58.6	Islet cell	Pancreas	Surgery	+
P8.3	M	32	85	Neuroendocrine	Pancreas	Surgery	+
P9.3	F	46	77	Glucagonoma	Pancreas	Chemotherapy/Sandostatin/surgery	+
P10.5	F	65	83	Gastrinoma	Duodenum	Chemotherapy	+
P11.6	M	60	114	Carcinoid	Unknown	Chemotherapy/Sandostatin	−

Patients are numbered from P1 to P11 followed by treatment cycle number. Sandostatin (Novartis AG Corp.) is a long-acting octreotide.